Astria Therapeutics to Present at Upcoming Investor Conferences

Astria Therapeutics (NASDAQ:ATXS) announced that CEO Jill C. Milne, Ph.D., will present an overview of the company and its lead program, STAR-0215, which targets hereditary angioedema (HAE), at two upcoming virtual investor conferences.

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/10/2021 - 08:00 AM

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:

H.C. Wainwright 23^rd Annual Global Investment Conference on September 13, 2021. The on-demand presentation will be available at 7:00am ET at the following link: https://journey.ct.events/view/5b3d4715-8ae5-4b39-9000-ba72d0444848
Oppenheimer Fall Healthcare, Life Sciences, and MedTech Summit on September 22, 2021. The presentation will be available at 2:55pm ET at the following link: https://wsw.com/webcast/oppenheimer16/catb/2735278

Webcasts of the events can be accessed from the investors section of www.astriatx.com. Archived replays will be available for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005022/en/

Astria:

Investor relations:
Andrea Matthews
investors@astriatx.com

Media:
Elizabeth Higgins
media@astriatx.com

Source: Astria Therapeutics, Inc.

Keep reading

More on ATXS

All ATXS news

Trending in the feed

AIIO

Robo.ai Reports September Revenue Exceeding US$100 Million and Expects Approximately US$600 Million for Full Year 2026 Open the live feed